Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a heart drug stop pneumonia after a stroke?

NCT ID NCT07528235

Prevention Sponsor: Tang-Du Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests the safety of a 7-day intravenous drip of propranolol (a drug usually used for heart conditions) to prevent pneumonia in 30 adults who have had a severe brain bleed. The goal is to find the best dose and see if it reduces lung infections. Participants must be treated within 24 hours of their stroke and have no current infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

10 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged \> 18 and ≤ 80 years of age; * Can be treated with the study drug within 24 h of symptom onset; * No fever or infection was observed upon admission; * NIHSS score ≥10; * Supratentorial parenchymal haematoma (≥10 mL); * GCS score ≥ 6; * Patients or their family members sign informed consent forms. Exclusion Criteria: * Infections within the last 4 weeks; * Use of antibiotics within the last 2 weeks; * Known pre-ICH dysphagia; * Secondary intracerebral hemorrhage or intraventricular hemorrhage resulting from trauma, vascular malformation, aneurysm, coagulopathy, anticoagulant drugs, thrombolysis, post-infarction hemorrhage transformation, hematopathy, moyamoya disease, primary or metastatic tumor, venous sinus thrombosis, vasculitis, and other definite causes; * Previous disability with pre-ICH mRS score ≥ 2; * Brainstem hemorrhage; * Life expectancy less than 14 days; * Death appeared imminent; * Pregnancy or within 30 d of delivery; * Previous use (within 1 month) of β-blockers or reserpine; * Bronchial asthma or COPD; * Cardiogenic shock; * Degree II-III atrioventricular blocks; * Severe or acute heart failure; * Heart rate \< 65 beats/min; * Known to be allergic to propranolol; * Severe liver or renal insufficiency; * History of malignant tumors; * Currently participating in other interventional clinical trials; * Currently, immunosuppressants and immunotherapies are being administered.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intracerebral hemorrhage are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intracerebral hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intracerebral hemorrhage Stroke-associated pneumonia (SAP)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Neurosurgery , Tangdu Hospital, Fourth Military Medical University

    Xi'an, Shaanxi, 710038, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.